Internal medicine

Adverse effect

Immunotherapy

Gastroenterology

Cancer

Oncology

Chemotherapy

Progressive disease

Response Evaluation Criteria in Solid Tumors

Nivolumab

Ipilimumab

Medicine

Journal of Clinical Oncology

Metastatic esophagogastric cancer treatments after failure of second-line chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced gastric or gastroesophageal junction cancers. We assessed the safety and efficacy of nivolumab and nivolumab plus ipilimumab in Western patients with chemotherapy-refractory esophagogastric cancers.

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer